JSI RESOURCES: Publications

The ‘Magic Bullet’ for HIV Viral Suppression? How Fixed-dose Combination Dolutegravir Antiretrovirals are Improving Viral Suppression among Children 10–14 Years on Antiretroviral Therapy in Zambia


Globally, viral suppression among children living with HIV (CLHIV) is at 40% compared with 67% among adults (UNAIDS, 2021). Zambia faced a similar challenge, which was compounded by limited availability of the more palatable and highly efficacious fixed-dose combination dolutegravir (DTG)-containing antiretrovirals, until pediatric ART guidelines were launched in 2020. In November 2020, with increased availability of pediatric DTG-containing antiretrovirals in the national ART program, the USAID DISCOVER-Health Project, implemented by JSI, started initiating and transitioning 10–14-year old CLHIV to DTG-containing regimens, in line with national HIV guidelines. This abstract was shared at the AIDS 2022 Conference. 

Partner with Us

We strive to build lasting relationships to produce better health outcomes for all.